Deerfield Management Company, L.P. (Series C) Anavex Life Sciences Corp. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 105,484 shares of AVXL stock, worth $910,326. This represents 0.01% of its overall portfolio holdings.
Number of Shares
105,484
Previous 81,890
28.81%
Holding current value
$910,326
Previous $345,000
73.62%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding AVXL
# of Institutions
155Shares Held
27.3MCall Options Held
515KPut Options Held
838K-
Black Rock Inc. New York, NY6.39MShares$55.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.74MShares$40.9 Million0.0% of portfolio
-
State Street Corp Boston, MA3.07MShares$26.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$16.3 Million0.0% of portfolio
-
Wealthgarden F.S. LLC El Segundo, CA910KShares$7.86 Million0.32% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $673M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...